Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...

Investing.com - Hims & Hers said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE: NVO), sending shares in the U.

Investing.com - U.S. stocks edged lower on Tuesday, as investors assessed a weaker-than-anticipated reading on consumer confidence and took some caution ahead of crucial quarterly ...

Elsewhere, gold prices ticked lower, but remained close to recent peaks as safe-haven demand was partly underpinned by ...

Meanwhile, Hims & Hers (NYSE: HIMS) warned that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE: NVO ), sending shares in the U.S. telehealth firm ...

In 2023, the government set up a commission for Well-Being to make recommendations and assessments regarding the well-being of children and young people in Denmark.On Tuesday, the commission gave its ...

Compounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...

Early yesterday morning, Unilever announced that its chief exec, Hein Schumacher (pictured), would be departing after less ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...